Tocilizumab in Schizophrenia
Phase 1
Recruiting
- Conditions
- Psychotic DisordersSchizophrenia
- Interventions
- Drug: Normal saline
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Brian Miller
- Target Recruit Count
- 20
- Registration Number
- NCT02874573
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
Siltuximab in Schizophrenia
Phase 1
Recruiting
- Conditions
- SchizophreniaPsychotic Disorders
- Interventions
- Drug: normal saline
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Brian Miller
- Target Recruit Count
- 30
- Registration Number
- NCT02796859
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
An Open-Label Trial of Tocilizumab in Schizophrenia
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Brian Miller
- Target Recruit Count
- 8
- Registration Number
- NCT01696929
- Locations
- 🇺🇸
Georgia Health Sciences University, Augusta, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath